WO2007107774A3 - Nouvelles méthodes de diagnostic et de traitement - Google Patents

Nouvelles méthodes de diagnostic et de traitement Download PDF

Info

Publication number
WO2007107774A3
WO2007107774A3 PCT/GB2007/001041 GB2007001041W WO2007107774A3 WO 2007107774 A3 WO2007107774 A3 WO 2007107774A3 GB 2007001041 W GB2007001041 W GB 2007001041W WO 2007107774 A3 WO2007107774 A3 WO 2007107774A3
Authority
WO
WIPO (PCT)
Prior art keywords
subunit
diagnostic
integrin alpha
cancer
therapeutic target
Prior art date
Application number
PCT/GB2007/001041
Other languages
English (en)
Other versions
WO2007107774A2 (fr
Inventor
Evy Lundgren-Aakerlund
Anja Bosserhoff
Original Assignee
Cartela R & D Ab
Smith Stephen Edward
Evy Lundgren-Aakerlund
Anja Bosserhoff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0605738A external-priority patent/GB0605738D0/en
Application filed by Cartela R & D Ab, Smith Stephen Edward, Evy Lundgren-Aakerlund, Anja Bosserhoff filed Critical Cartela R & D Ab
Publication of WO2007107774A2 publication Critical patent/WO2007107774A2/fr
Publication of WO2007107774A3 publication Critical patent/WO2007107774A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne l'utilisation d'un composé comprenant un groupe de liaison capable de se fixer de manière sélective à la sous-unité alpha-10 de l'intégrine ou à un de ses hétérodimères, dans la préparation (a) d'un médicament destiné au traitement de tumeurs malignes, (b) d'un agent diagnostique ou pronostique pour des tumeurs malignes et (c) d'un agent permettant de détecter des cellules de tumeurs malignes et/ou d'obtenir une image de celles-ci. De préférence, la tumeur est un mélanome malin. Dans un mode de réalisation préféré, le composé comprend un anticorps ou un fragment se fixant à un antigène ou un dérivé associé, ou est constitué d'un anticorps ou d'un fragment se fixant à un antigène ou d'un dérivé associé. L'invention concerne également des méthodes destinées au traitement, au diagnostic et à la production d'images de cellules de tumeurs malignes.
PCT/GB2007/001041 2006-03-22 2007-03-22 Nouvelles méthodes de diagnostic et de traitement WO2007107774A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US78444506P 2006-03-22 2006-03-22
US60/784,445 2006-03-22
GB0605738A GB0605738D0 (en) 2006-03-22 2006-03-22 Novel diagnostic and therapeutic methods
GB0605738.4 2006-03-22

Publications (2)

Publication Number Publication Date
WO2007107774A2 WO2007107774A2 (fr) 2007-09-27
WO2007107774A3 true WO2007107774A3 (fr) 2008-04-10

Family

ID=38522791

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/001041 WO2007107774A2 (fr) 2006-03-22 2007-03-22 Nouvelles méthodes de diagnostic et de traitement

Country Status (1)

Country Link
WO (1) WO2007107774A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107427575A (zh) * 2015-02-16 2017-12-01 辛特拉股份公司 Cns中的恶性肿瘤的检测和治疗

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2140269B1 (fr) 2007-03-27 2013-11-20 Immunovia AB Procédé, assemblage et utilisation de celui-ci
GB201103726D0 (en) * 2011-03-04 2011-04-20 Immunovia Ab Method, array and use thereof
CN103285134A (zh) * 2012-03-05 2013-09-11 王海城 消瘀液
JP2022530339A (ja) * 2019-04-15 2022-06-29 タルギンタ エービー インテグリンα１０および侵攻性癌型
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
WO2024047172A1 (fr) * 2022-08-31 2024-03-07 Targinta Ab Conjugué anticorps-médicament d'intégrine alpha10

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068848A2 (fr) * 2000-03-01 2001-09-20 Genentech, Inc. Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
WO2002077013A2 (fr) * 2001-03-27 2002-10-03 Human Genome Sciences, Inc. Proteines secretees humaines
WO2004016758A2 (fr) * 2002-08-15 2004-02-26 Genzyme Corporation Motifs d'expression de cellules endotheliales cerebrales
EP1407787A1 (fr) * 2001-06-20 2004-04-14 Sumitomo Pharmaceuticals Company, Limited Procede facilitant le transfert d'acides nucleiques
GB2429012A (en) * 2005-08-12 2007-02-14 Cartela Ab Polypeptides capable of binding an integrin I-domain.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068848A2 (fr) * 2000-03-01 2001-09-20 Genentech, Inc. Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
WO2002077013A2 (fr) * 2001-03-27 2002-10-03 Human Genome Sciences, Inc. Proteines secretees humaines
EP1407787A1 (fr) * 2001-06-20 2004-04-14 Sumitomo Pharmaceuticals Company, Limited Procede facilitant le transfert d'acides nucleiques
WO2004016758A2 (fr) * 2002-08-15 2004-02-26 Genzyme Corporation Motifs d'expression de cellules endotheliales cerebrales
GB2429012A (en) * 2005-08-12 2007-02-14 Cartela Ab Polypeptides capable of binding an integrin I-domain.

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CERRI AMILCARE ET AL: "Immunohistochemical localization of a novel beta-1 integrin in normal and pathologic squamous epithelia", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 102, no. 2, 1994, pages 247 - 252, XP002468420, ISSN: 0022-202X *
CRISTOFORONI P ET AL: "Expression of a novel beta-1 integrin in the dysplastic progression of the cervical epithelium", GYNECOLOGIC ONCOLOGY, vol. 58, no. 3, 1995, pages 319 - 326, XP002468419, ISSN: 0090-8258 *
HSU MEI-YU ET AL: "Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma", AMERICAN JOURNAL OF PATHOLOGY, vol. 153, no. 5, November 1998 (1998-11-01), pages 1435 - 1442, XP002468421, ISSN: 0002-9440 *
WENKE ANN-KATHRIN ET AL: "Expression of integrin alpha 10 is induced in malignant melanoma", CELLULAR ONCOLOGY, IOS PRESS, LONDON, GB, vol. 29, no. 5, 21 September 2007 (2007-09-21), pages 373 - 386, XP009095737, ISSN: 1570-5870 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107427575A (zh) * 2015-02-16 2017-12-01 辛特拉股份公司 Cns中的恶性肿瘤的检测和治疗

Also Published As

Publication number Publication date
WO2007107774A2 (fr) 2007-09-27

Similar Documents

Publication Publication Date Title
WO2007107774A3 (fr) Nouvelles méthodes de diagnostic et de traitement
MX2010000405A (es) Seleccion de farmacos para terapia de cancer de pulmon usando arreglos a base de anticuerpos.
WO2007081767A3 (fr) Utilisation de he4 et d'autres marqueurs biochimiques dans l'évaluation de cancers de l'endomètre et de l'utérus
WO2005008248A3 (fr) Diagnostique et traitement du cancer des cervicales
EP2618146A3 (fr) Sélection d'un médicament pour la thérapie du cancer du sein à partir des matrices d'anticorps
EP2196474A3 (fr) Cibles thérapeutiques dans le cancer
WO2008008483A3 (fr) Compositions basées sur dendrimères et procédés d'utilisation correspondants
WO2005031001A3 (fr) Nouvelles cibles therapeutiques pour le traitement du cancer
WO2008053330A3 (fr) Anticorps monoclonaux et fragments de ceux-ci dirigés contre le récepteur de type ii de l'hormone antimüllérienne humaine (amhr-ii)
WO2006015079A3 (fr) Agents de liaison de la famille erm et leur utilisation dans le diagnostic et le traitement d'etats proliferatifs
WO2010081001A3 (fr) Fusions de gène récurrent dans le cancer
WO2008010101A3 (fr) Anticorps antagoniste destiné au traitement du cancer
WO2007109321A3 (fr) Anticorps modifiés dirigés contre l'antigène de cellules souches prostatiques servant à cibler le cancer
WO2010042815A3 (fr) Fragments d'anticorps vhh utilisables dans le cadre de la détection et du traitement du cancer
WO2006033766A3 (fr) Compositions a base de dendrimeres et procedes d'utilisation de celles-ci
WO2005094348A3 (fr) Anticorps anti-lfl2 pour le diagnostic, le pronostic et le traitement d'un cancer
WO2009029591A3 (fr) Anticorps monoclonal qui se lie à met dans des tissus fixés au formaldéhyde et incorporés dans de la paraffine et procédés apparentés
WO2009009203A3 (fr) Compositions à base de dendrimères et procédés pour les utiliser
WO2003055917A3 (fr) Nouvelles methodes de diagnostic et de traitement de tumeurs
WO2004067570A3 (fr) Diagnostic et traitement du cancer de la prostate
WO2009019365A3 (fr) Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal
WO2007149948A3 (fr) Compositions et procédés de diagnostic et de traitement des tumeurs
WO2007146668A3 (fr) Utilisation d'imp3 en tant que marqueur pronostique de cancer
WO2011119888A3 (fr) N-cadhérine: une cible pour diagnostic et traitement du cancer
WO2009020645A3 (fr) Protéine de matriptase et utilisations de celle-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07732105

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07732105

Country of ref document: EP

Kind code of ref document: A2